Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Immunotherapy, Adoptive | 102 | 2024 | 1504 | 16.610 |
Why?
|
Receptors, Antigen, T-Cell | 58 | 2024 | 2570 | 7.930 |
Why?
|
T-Lymphocytes | 92 | 2024 | 10260 | 6.540 |
Why?
|
Antigens, CD19 | 22 | 2024 | 442 | 4.180 |
Why?
|
Hematologic Neoplasms | 16 | 2024 | 1926 | 3.680 |
Why?
|
Antigens, Neoplasm | 17 | 2024 | 1996 | 2.120 |
Why?
|
B-Cell Maturation Antigen | 8 | 2024 | 148 | 1.950 |
Why?
|
Multiple Myeloma | 16 | 2024 | 5189 | 1.840 |
Why?
|
Glioblastoma | 10 | 2024 | 3458 | 1.800 |
Why?
|
Neoplasms | 28 | 2024 | 22344 | 1.780 |
Why?
|
Neurotoxicity Syndromes | 6 | 2024 | 302 | 1.760 |
Why?
|
Genetic Engineering | 9 | 2022 | 933 | 1.710 |
Why?
|
Tumor Microenvironment | 13 | 2024 | 3942 | 1.510 |
Why?
|
Immunotherapy | 19 | 2021 | 4746 | 1.500 |
Why?
|
Lymphoma, B-Cell | 5 | 2024 | 943 | 1.370 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 3 | 2024 | 273 | 1.350 |
Why?
|
Recombinant Fusion Proteins | 10 | 2019 | 3733 | 1.170 |
Why?
|
Xenograft Model Antitumor Assays | 8 | 2024 | 3604 | 1.050 |
Why?
|
GPI-Linked Proteins | 4 | 2024 | 472 | 1.020 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 7 | 2022 | 1643 | 1.020 |
Why?
|
Antigen-Presenting Cells | 7 | 2020 | 960 | 1.000 |
Why?
|
Antibodies, Bispecific | 2 | 2019 | 203 | 0.950 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 | 2022 | 1559 | 0.910 |
Why?
|
Receptors, Antigen | 2 | 2014 | 51 | 0.890 |
Why?
|
Transduction, Genetic | 3 | 2020 | 898 | 0.800 |
Why?
|
Lymphoma | 3 | 2022 | 1896 | 0.800 |
Why?
|
Humans | 174 | 2024 | 766117 | 0.790 |
Why?
|
4-1BB Ligand | 2 | 2020 | 28 | 0.790 |
Why?
|
Bone Marrow Neoplasms | 1 | 2022 | 101 | 0.770 |
Why?
|
Cytotoxicity, Immunologic | 6 | 2021 | 1346 | 0.770 |
Why?
|
RNA, Small Cytoplasmic | 1 | 2020 | 17 | 0.710 |
Why?
|
Accreditation | 1 | 2024 | 476 | 0.710 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2024 | 497 | 0.700 |
Why?
|
Endopeptidases | 1 | 2024 | 760 | 0.700 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2024 | 1407 | 0.690 |
Why?
|
Lymphoma, Follicular | 2 | 2022 | 459 | 0.670 |
Why?
|
Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2019 | 40 | 0.670 |
Why?
|
Lymphocyte Activation | 14 | 2021 | 5503 | 0.660 |
Why?
|
Lymphoma, Mantle-Cell | 2 | 2019 | 238 | 0.650 |
Why?
|
Research Personnel | 1 | 2024 | 589 | 0.630 |
Why?
|
Pancytopenia | 1 | 2019 | 102 | 0.620 |
Why?
|
Lentivirus | 2 | 2022 | 518 | 0.610 |
Why?
|
Pancreatic Neoplasms | 4 | 2024 | 5454 | 0.600 |
Why?
|
Tumor Burden | 1 | 2024 | 1889 | 0.600 |
Why?
|
Brain Neoplasms | 8 | 2024 | 9065 | 0.590 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 3 | 2022 | 1433 | 0.570 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 1 | 2019 | 196 | 0.570 |
Why?
|
T-Cell Antigen Receptor Specificity | 4 | 2019 | 89 | 0.570 |
Why?
|
United States Food and Drug Administration | 2 | 2024 | 1673 | 0.520 |
Why?
|
Neoplasms, Second Primary | 1 | 2024 | 1056 | 0.520 |
Why?
|
ZAP-70 Protein-Tyrosine Kinase | 1 | 2016 | 69 | 0.510 |
Why?
|
Immunity, Cellular | 3 | 2020 | 1557 | 0.510 |
Why?
|
Flow Cytometry | 6 | 2024 | 5881 | 0.510 |
Why?
|
Lymphoma, T-Cell | 1 | 2018 | 308 | 0.510 |
Why?
|
Animals | 46 | 2024 | 168800 | 0.500 |
Why?
|
Central Nervous System Neoplasms | 2 | 2022 | 918 | 0.470 |
Why?
|
Immunologic Factors | 2 | 2020 | 1592 | 0.460 |
Why?
|
Cell Line, Tumor | 16 | 2024 | 17071 | 0.460 |
Why?
|
Sulfonamides | 1 | 2024 | 1980 | 0.460 |
Why?
|
Biological Products | 2 | 2022 | 947 | 0.440 |
Why?
|
Autoimmune Diseases | 3 | 2020 | 2249 | 0.440 |
Why?
|
Pyrazoles | 5 | 2022 | 2031 | 0.420 |
Why?
|
Apoptosis | 6 | 2024 | 9508 | 0.400 |
Why?
|
Virus Diseases | 2 | 2020 | 720 | 0.400 |
Why?
|
CD4-Positive T-Lymphocytes | 7 | 2023 | 4408 | 0.390 |
Why?
|
Mice | 23 | 2024 | 81839 | 0.390 |
Why?
|
Pleural Neoplasms | 2 | 2014 | 584 | 0.380 |
Why?
|
Pyrimidines | 5 | 2022 | 3050 | 0.370 |
Why?
|
Adaptive Immunity | 1 | 2016 | 733 | 0.360 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2024 | 9378 | 0.350 |
Why?
|
Mesothelioma | 2 | 2014 | 774 | 0.350 |
Why?
|
Receptors, Immunologic | 4 | 2017 | 1416 | 0.330 |
Why?
|
Mice, Inbred NOD | 5 | 2019 | 1837 | 0.320 |
Why?
|
Skin | 2 | 2019 | 4482 | 0.320 |
Why?
|
B-Lymphocytes | 2 | 2020 | 4782 | 0.310 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2022 | 3637 | 0.310 |
Why?
|
K562 Cells | 3 | 2020 | 644 | 0.310 |
Why?
|
Cancer Vaccines | 2 | 2016 | 1042 | 0.310 |
Why?
|
Echovirus Infections | 1 | 2008 | 7 | 0.300 |
Why?
|
Enterovirus B, Human | 1 | 2008 | 49 | 0.290 |
Why?
|
Cytokines | 7 | 2023 | 7426 | 0.290 |
Why?
|
Leukemia, B-Cell | 2 | 2019 | 86 | 0.280 |
Why?
|
Zebrafish | 3 | 2024 | 3035 | 0.270 |
Why?
|
Cell Proliferation | 7 | 2019 | 10433 | 0.270 |
Why?
|
Clinical Trials as Topic | 8 | 2023 | 8038 | 0.260 |
Why?
|
Adoptive Transfer | 2 | 2022 | 827 | 0.260 |
Why?
|
Interleukin-7 | 2 | 2023 | 146 | 0.260 |
Why?
|
Anaphylaxis | 1 | 2013 | 738 | 0.250 |
Why?
|
Tumor Escape | 2 | 2021 | 371 | 0.250 |
Why?
|
Hematopoietic Stem Cell Transplantation | 5 | 2024 | 5752 | 0.250 |
Why?
|
Signal Transduction | 6 | 2021 | 23605 | 0.240 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2019 | 3112 | 0.240 |
Why?
|
Single-Cell Analysis | 3 | 2021 | 2536 | 0.240 |
Why?
|
Antigens, CD7 | 1 | 2024 | 29 | 0.240 |
Why?
|
T-Lymphocyte Subsets | 4 | 2017 | 1814 | 0.230 |
Why?
|
CD8-Positive T-Lymphocytes | 6 | 2024 | 4649 | 0.230 |
Why?
|
Molecular Targeted Therapy | 1 | 2015 | 2824 | 0.230 |
Why?
|
Antigens, CD | 6 | 2024 | 4025 | 0.220 |
Why?
|
Protein Kinase Inhibitors | 1 | 2020 | 5695 | 0.220 |
Why?
|
Bone Marrow | 4 | 2022 | 2916 | 0.220 |
Why?
|
Immunity, Innate | 1 | 2016 | 3079 | 0.220 |
Why?
|
Antibodies, Monoclonal | 1 | 2020 | 9237 | 0.210 |
Why?
|
Milk, Human | 1 | 2008 | 490 | 0.210 |
Why?
|
Virus Latency | 2 | 2023 | 359 | 0.210 |
Why?
|
Immune Tolerance | 4 | 2021 | 2324 | 0.210 |
Why?
|
Herpesvirus 6, Human | 1 | 2023 | 96 | 0.210 |
Why?
|
T-Lymphocytes, Cytotoxic | 4 | 2009 | 1801 | 0.210 |
Why?
|
bcl-X Protein | 1 | 2024 | 412 | 0.200 |
Why?
|
Orbit | 4 | 2001 | 458 | 0.200 |
Why?
|
Immunomodulation | 2 | 2016 | 548 | 0.200 |
Why?
|
Infant, Premature, Diseases | 1 | 2008 | 712 | 0.190 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 230 | 0.190 |
Why?
|
Virus Activation | 1 | 2023 | 322 | 0.190 |
Why?
|
Single-Chain Antibodies | 2 | 2019 | 114 | 0.190 |
Why?
|
Burkitt Lymphoma | 1 | 2023 | 338 | 0.180 |
Why?
|
Tolnaftate | 1 | 2020 | 2 | 0.180 |
Why?
|
Immunologic Memory | 3 | 2021 | 1377 | 0.180 |
Why?
|
Receptors, Nerve Growth Factor | 1 | 2002 | 199 | 0.180 |
Why?
|
Graves Disease | 3 | 1999 | 239 | 0.180 |
Why?
|
Leukocytes, Mononuclear | 4 | 2022 | 1852 | 0.180 |
Why?
|
Gene Transfer Techniques | 3 | 2016 | 1206 | 0.180 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2008 | 1354 | 0.180 |
Why?
|
Transgenes | 1 | 2024 | 1014 | 0.180 |
Why?
|
HLA Antigens | 2 | 2003 | 1338 | 0.180 |
Why?
|
Inflammation | 2 | 2020 | 10860 | 0.170 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 299 | 0.170 |
Why?
|
Biopsy | 2 | 2024 | 6768 | 0.170 |
Why?
|
Ribonucleoproteins | 2 | 2021 | 359 | 0.170 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2024 | 698 | 0.170 |
Why?
|
Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2020 | 121 | 0.170 |
Why?
|
Eyebrows | 2 | 2001 | 38 | 0.170 |
Why?
|
Mice, SCID | 3 | 2019 | 2626 | 0.160 |
Why?
|
Philadelphia Chromosome | 1 | 2020 | 119 | 0.160 |
Why?
|
Ophthalmologic Surgical Procedures | 2 | 1999 | 354 | 0.160 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2002 | 588 | 0.160 |
Why?
|
Women's Rights | 1 | 2019 | 66 | 0.160 |
Why?
|
HEK293 Cells | 4 | 2021 | 4263 | 0.160 |
Why?
|
Chemotactic Factors | 1 | 1999 | 196 | 0.160 |
Why?
|
Tumor Cells, Cultured | 5 | 2021 | 6102 | 0.160 |
Why?
|
Lymphocytes | 3 | 2024 | 2602 | 0.160 |
Why?
|
Macrophage Activation | 1 | 2022 | 553 | 0.160 |
Why?
|
Serine Endopeptidases | 1 | 2024 | 1027 | 0.160 |
Why?
|
Adult | 25 | 2024 | 223139 | 0.160 |
Why?
|
Reference Standards | 1 | 2022 | 1011 | 0.160 |
Why?
|
Aged | 22 | 2024 | 171219 | 0.160 |
Why?
|
Rhabdomyosarcoma | 1 | 2021 | 354 | 0.150 |
Why?
|
Codon, Nonsense | 1 | 2019 | 288 | 0.150 |
Why?
|
Craniotomy | 2 | 2001 | 737 | 0.150 |
Why?
|
Male | 31 | 2024 | 363935 | 0.150 |
Why?
|
Lymphoid Tissue | 1 | 2019 | 444 | 0.150 |
Why?
|
Open Reading Frames | 1 | 2021 | 820 | 0.150 |
Why?
|
Glioma | 2 | 2024 | 3491 | 0.140 |
Why?
|
Glutamate Carboxypeptidase II | 1 | 2018 | 90 | 0.140 |
Why?
|
Fatal Outcome | 2 | 2019 | 1836 | 0.140 |
Why?
|
Cell Death | 2 | 2022 | 1676 | 0.140 |
Why?
|
Prolactin | 1 | 1999 | 626 | 0.140 |
Why?
|
Treatment Outcome | 12 | 2024 | 65219 | 0.140 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2021 | 827 | 0.140 |
Why?
|
Opportunistic Infections | 1 | 2020 | 376 | 0.140 |
Why?
|
Granzymes | 1 | 2019 | 278 | 0.140 |
Why?
|
Gastrointestinal Tract | 1 | 2023 | 834 | 0.140 |
Why?
|
Bioreactors | 1 | 2018 | 244 | 0.140 |
Why?
|
E-Selectin | 1 | 2019 | 576 | 0.140 |
Why?
|
Protein Engineering | 3 | 2019 | 550 | 0.140 |
Why?
|
Guidelines as Topic | 2 | 2020 | 1394 | 0.140 |
Why?
|
Orbital Neoplasms | 1 | 1999 | 222 | 0.140 |
Why?
|
Ubiquitin-Protein Ligases | 2 | 2023 | 1897 | 0.140 |
Why?
|
Receptors, Transforming Growth Factor beta | 1 | 2018 | 305 | 0.140 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2021 | 1374 | 0.130 |
Why?
|
Immunization | 1 | 2021 | 1218 | 0.130 |
Why?
|
Interferon-gamma | 3 | 2022 | 3159 | 0.130 |
Why?
|
Melphalan | 1 | 2018 | 425 | 0.130 |
Why?
|
Cell Differentiation | 3 | 2024 | 11642 | 0.130 |
Why?
|
Biotechnology | 1 | 2018 | 284 | 0.130 |
Why?
|
Endonucleases | 1 | 2019 | 372 | 0.130 |
Why?
|
Adenine | 3 | 2017 | 994 | 0.130 |
Why?
|
Middle Aged | 22 | 2024 | 223083 | 0.130 |
Why?
|
Induced Pluripotent Stem Cells | 3 | 2024 | 1884 | 0.130 |
Why?
|
Disease Susceptibility | 2 | 2019 | 1790 | 0.130 |
Why?
|
Chimerism | 2 | 2014 | 154 | 0.120 |
Why?
|
Leukemia | 1 | 2023 | 1522 | 0.120 |
Why?
|
Peptides | 4 | 2021 | 4338 | 0.120 |
Why?
|
HIV-1 | 3 | 2022 | 6948 | 0.120 |
Why?
|
Skin Transplantation | 2 | 1999 | 1097 | 0.120 |
Why?
|
Exanthema | 1 | 2019 | 503 | 0.120 |
Why?
|
Fever | 2 | 2019 | 1607 | 0.120 |
Why?
|
Female | 30 | 2024 | 396233 | 0.120 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2021 | 1362 | 0.120 |
Why?
|
Recurrence | 2 | 2024 | 8494 | 0.110 |
Why?
|
Glaucoma, Angle-Closure | 2 | 2001 | 192 | 0.110 |
Why?
|
Neoplasms, Experimental | 1 | 2019 | 1227 | 0.110 |
Why?
|
Antibodies, Viral | 2 | 2022 | 3214 | 0.110 |
Why?
|
Hemangioma | 1 | 1999 | 724 | 0.110 |
Why?
|
Eye Diseases | 1 | 1999 | 660 | 0.110 |
Why?
|
Histiocytosis | 1 | 2014 | 40 | 0.110 |
Why?
|
Antigens, Surface | 1 | 2018 | 1616 | 0.110 |
Why?
|
Sepsis | 1 | 2008 | 2603 | 0.110 |
Why?
|
Protein Binding | 3 | 2019 | 9301 | 0.110 |
Why?
|
Eyelids | 3 | 2001 | 278 | 0.110 |
Why?
|
Disease Models, Animal | 3 | 2019 | 18321 | 0.110 |
Why?
|
Physicians, Women | 1 | 2019 | 516 | 0.110 |
Why?
|
Piperidines | 3 | 2017 | 1664 | 0.110 |
Why?
|
Compassionate Use Trials | 1 | 2013 | 49 | 0.110 |
Why?
|
Immunoglobulin Fragments | 1 | 2013 | 83 | 0.100 |
Why?
|
Cell Line | 5 | 2019 | 15546 | 0.100 |
Why?
|
Antineoplastic Agents | 4 | 2023 | 13635 | 0.100 |
Why?
|
Dependovirus | 2 | 2009 | 721 | 0.100 |
Why?
|
Schools, Medical | 1 | 2019 | 882 | 0.100 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2024 | 1762 | 0.100 |
Why?
|
Surgery, Plastic | 1 | 1999 | 652 | 0.100 |
Why?
|
Glycoproteins | 1 | 2019 | 2196 | 0.100 |
Why?
|
Proto-Oncogene Proteins | 1 | 2024 | 4521 | 0.100 |
Why?
|
Disease Management | 2 | 2019 | 2531 | 0.100 |
Why?
|
Killer Cells, Natural | 1 | 2021 | 2206 | 0.090 |
Why?
|
Peptide Fragments | 1 | 2024 | 5126 | 0.090 |
Why?
|
Forkhead Transcription Factors | 1 | 2019 | 1623 | 0.090 |
Why?
|
Antigen Presentation | 3 | 2021 | 1250 | 0.090 |
Why?
|
Anterior Chamber | 2 | 2001 | 194 | 0.090 |
Why?
|
Proteome | 1 | 2021 | 1896 | 0.090 |
Why?
|
Hodgkin Disease | 1 | 2019 | 1383 | 0.090 |
Why?
|
Autoimmunity | 1 | 2019 | 1354 | 0.090 |
Why?
|
Demography | 1 | 2016 | 1641 | 0.090 |
Why?
|
United States | 6 | 2024 | 72920 | 0.090 |
Why?
|
Histocompatibility Antigens | 3 | 2024 | 479 | 0.090 |
Why?
|
HIV Infections | 3 | 2022 | 17535 | 0.090 |
Why?
|
Leadership | 1 | 2019 | 1394 | 0.080 |
Why?
|
Light Coagulation | 1 | 1990 | 72 | 0.080 |
Why?
|
Ocular Hypotension | 1 | 1990 | 23 | 0.080 |
Why?
|
Phagocytosis | 2 | 2014 | 1518 | 0.080 |
Why?
|
Melanoma | 2 | 2022 | 5695 | 0.080 |
Why?
|
Choroid Diseases | 1 | 1990 | 60 | 0.080 |
Why?
|
Coculture Techniques | 3 | 2021 | 1336 | 0.080 |
Why?
|
Risk Assessment | 2 | 2022 | 24276 | 0.080 |
Why?
|
Orbital Implants | 2 | 1999 | 20 | 0.080 |
Why?
|
Cell Aggregation | 2 | 2019 | 238 | 0.080 |
Why?
|
Organ Transplantation | 1 | 2019 | 1172 | 0.080 |
Why?
|
Immune System | 1 | 2014 | 799 | 0.080 |
Why?
|
Antigens | 1 | 2014 | 1437 | 0.070 |
Why?
|
Patient Selection | 2 | 2020 | 4249 | 0.070 |
Why?
|
Muscle Proteins | 1 | 2013 | 1160 | 0.070 |
Why?
|
Administration, Oral | 1 | 2016 | 4016 | 0.070 |
Why?
|
Antibodies | 2 | 2014 | 2415 | 0.070 |
Why?
|
Diagnosis, Differential | 2 | 2019 | 12976 | 0.070 |
Why?
|
Critical Care | 1 | 2020 | 2714 | 0.070 |
Why?
|
Membrane Proteins | 1 | 2024 | 7850 | 0.070 |
Why?
|
Parvoviridae Infections | 1 | 2007 | 39 | 0.070 |
Why?
|
Receptors, Interleukin-6 | 2 | 2020 | 227 | 0.070 |
Why?
|
Retrospective Studies | 8 | 2024 | 81565 | 0.070 |
Why?
|
Drug Delivery Systems | 1 | 2018 | 2210 | 0.070 |
Why?
|
Neoplasm, Residual | 2 | 2022 | 1009 | 0.070 |
Why?
|
Nanoparticles | 1 | 2018 | 1966 | 0.070 |
Why?
|
Cell Movement | 1 | 2018 | 5196 | 0.070 |
Why?
|
Proteins | 1 | 2021 | 5995 | 0.070 |
Why?
|
Adenocarcinoma | 1 | 2024 | 6363 | 0.070 |
Why?
|
Gene Expression | 1 | 2019 | 7582 | 0.070 |
Why?
|
Graft vs Host Disease | 1 | 2019 | 3079 | 0.070 |
Why?
|
Protein Kinases | 1 | 2013 | 1611 | 0.060 |
Why?
|
Macrophages | 1 | 2021 | 5776 | 0.060 |
Why?
|
Capsid Proteins | 1 | 2009 | 467 | 0.060 |
Why?
|
Bacterial Proteins | 1 | 2019 | 3830 | 0.060 |
Why?
|
Phenotype | 3 | 2021 | 16716 | 0.060 |
Why?
|
Diagnostic Imaging | 1 | 2019 | 3530 | 0.060 |
Why?
|
Stem Cell Transplantation | 1 | 2014 | 1600 | 0.060 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 9527 | 0.060 |
Why?
|
Hepatocytes | 2 | 2009 | 1246 | 0.060 |
Why?
|
Ovarian Neoplasms | 2 | 2017 | 4904 | 0.060 |
Why?
|
Follow-Up Studies | 3 | 2023 | 39243 | 0.060 |
Why?
|
Capsid | 1 | 2007 | 435 | 0.060 |
Why?
|
Anemia | 1 | 2014 | 1514 | 0.060 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2016 | 5336 | 0.060 |
Why?
|
Ligands | 2 | 2019 | 3274 | 0.050 |
Why?
|
Immunohistochemistry | 1 | 2017 | 11035 | 0.050 |
Why?
|
Evidence-Based Medicine | 1 | 2015 | 3690 | 0.050 |
Why?
|
Roseolovirus Infections | 1 | 2023 | 50 | 0.050 |
Why?
|
Transforming Growth Factor beta | 2 | 2023 | 1996 | 0.050 |
Why?
|
Drug Approval | 2 | 2020 | 820 | 0.050 |
Why?
|
Glaucoma, Open-Angle | 1 | 1990 | 742 | 0.050 |
Why?
|
bcl-2 Homologous Antagonist-Killer Protein | 1 | 2023 | 70 | 0.050 |
Why?
|
Genes, MHC Class I | 1 | 2003 | 236 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3111 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3233 | 0.050 |
Why?
|
Uveal Diseases | 1 | 2001 | 45 | 0.050 |
Why?
|
Cells, Cultured | 4 | 2019 | 18967 | 0.050 |
Why?
|
Transplantation, Autologous | 2 | 2018 | 2125 | 0.050 |
Why?
|
Interleukin-15 | 2 | 2018 | 186 | 0.050 |
Why?
|
Biology | 1 | 2024 | 293 | 0.050 |
Why?
|
Interleukin Receptor Common gamma Subunit | 1 | 2021 | 89 | 0.050 |
Why?
|
Eye Enucleation | 2 | 1998 | 128 | 0.050 |
Why?
|
Membrane Microdomains | 1 | 2002 | 203 | 0.050 |
Why?
|
Combined Modality Therapy | 3 | 2018 | 8525 | 0.050 |
Why?
|
Orbital Pseudotumor | 1 | 2001 | 42 | 0.050 |
Why?
|
Gene Expression Regulation, Viral | 1 | 2023 | 434 | 0.050 |
Why?
|
CD40 Ligand | 1 | 2003 | 528 | 0.050 |
Why?
|
Ciliary Body | 1 | 2001 | 168 | 0.040 |
Why?
|
N-Acetylglucosaminyltransferases | 1 | 2022 | 168 | 0.040 |
Why?
|
Diterpenes | 1 | 2021 | 169 | 0.040 |
Why?
|
Myocardium | 1 | 2013 | 4766 | 0.040 |
Why?
|
Prosthesis Implantation | 3 | 1999 | 594 | 0.040 |
Why?
|
Membrane Glycoproteins | 3 | 2003 | 3692 | 0.040 |
Why?
|
Caspases | 1 | 2023 | 881 | 0.040 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2004 | 1441 | 0.040 |
Why?
|
Immunoglobulins | 1 | 2003 | 853 | 0.040 |
Why?
|
Time Factors | 3 | 2016 | 40108 | 0.040 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2021 | 304 | 0.040 |
Why?
|
Cell Separation | 2 | 2002 | 1718 | 0.040 |
Why?
|
Microspheres | 1 | 2003 | 773 | 0.040 |
Why?
|
Chromones | 1 | 1999 | 148 | 0.040 |
Why?
|
NIH 3T3 Cells | 1 | 2021 | 651 | 0.040 |
Why?
|
Genetic Vectors | 1 | 2009 | 3400 | 0.040 |
Why?
|
Breast Feeding | 1 | 2008 | 1363 | 0.040 |
Why?
|
Acidaminococcus | 1 | 2019 | 9 | 0.040 |
Why?
|
CD4-CD8 Ratio | 1 | 2019 | 114 | 0.040 |
Why?
|
Azepines | 1 | 2021 | 328 | 0.040 |
Why?
|
RNA, Viral | 1 | 2008 | 2868 | 0.040 |
Why?
|
Cell Polarity | 1 | 2002 | 636 | 0.040 |
Why?
|
Fucose | 1 | 2019 | 115 | 0.040 |
Why?
|
Jurkat Cells | 1 | 2021 | 738 | 0.040 |
Why?
|
Oxidative Phosphorylation | 1 | 2021 | 502 | 0.040 |
Why?
|
Ubiquitination | 1 | 2023 | 1000 | 0.040 |
Why?
|
Remission, Spontaneous | 1 | 2019 | 384 | 0.040 |
Why?
|
Mice, Inbred Strains | 1 | 2021 | 1769 | 0.040 |
Why?
|
Phthalazines | 1 | 2021 | 397 | 0.040 |
Why?
|
Prognosis | 1 | 2019 | 29912 | 0.040 |
Why?
|
Interleukin-6 | 2 | 2020 | 3227 | 0.040 |
Why?
|
Young Adult | 3 | 2020 | 59868 | 0.040 |
Why?
|
Child | 4 | 2023 | 80573 | 0.040 |
Why?
|
Blepharoplasty | 1 | 1999 | 59 | 0.040 |
Why?
|
Electroporation | 2 | 2014 | 238 | 0.040 |
Why?
|
Ethmoid Sinus | 1 | 1998 | 58 | 0.040 |
Why?
|
Frontal Sinus | 1 | 1998 | 51 | 0.040 |
Why?
|
Infant, Premature | 1 | 2008 | 2121 | 0.040 |
Why?
|
Mucocele | 1 | 1998 | 51 | 0.040 |
Why?
|
Silicones | 1 | 2018 | 228 | 0.040 |
Why?
|
Synthetic Biology | 1 | 2020 | 185 | 0.040 |
Why?
|
Pluripotent Stem Cells | 1 | 2024 | 808 | 0.040 |
Why?
|
Polytetrafluoroethylene | 1 | 1998 | 242 | 0.040 |
Why?
|
Coated Materials, Biocompatible | 1 | 1999 | 314 | 0.040 |
Why?
|
Drug Synergism | 2 | 1999 | 1754 | 0.040 |
Why?
|
Ferritins | 1 | 2020 | 600 | 0.040 |
Why?
|
Laboratories | 1 | 2021 | 463 | 0.040 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2017 | 2425 | 0.040 |
Why?
|
Myeloablative Agonists | 1 | 2018 | 215 | 0.040 |
Why?
|
Blood Proteins | 1 | 2002 | 1186 | 0.040 |
Why?
|
Glycolysis | 1 | 2021 | 837 | 0.030 |
Why?
|
Paranasal Sinus Diseases | 1 | 1998 | 121 | 0.030 |
Why?
|
Eyelid Diseases | 1 | 1999 | 155 | 0.030 |
Why?
|
C-Reactive Protein | 2 | 2020 | 3853 | 0.030 |
Why?
|
Epidermal Growth Factor | 1 | 1999 | 697 | 0.030 |
Why?
|
Epigenesis, Genetic | 2 | 2021 | 3818 | 0.030 |
Why?
|
Alleles | 2 | 2021 | 6892 | 0.030 |
Why?
|
Chemotaxis | 1 | 1999 | 596 | 0.030 |
Why?
|
Permeability | 1 | 2018 | 726 | 0.030 |
Why?
|
Feasibility Studies | 2 | 2020 | 5300 | 0.030 |
Why?
|
Animals, Genetically Modified | 1 | 2021 | 1563 | 0.030 |
Why?
|
Glycosylation | 1 | 2019 | 1099 | 0.030 |
Why?
|
Morpholines | 1 | 1999 | 584 | 0.030 |
Why?
|
SOXB1 Transcription Factors | 1 | 2018 | 283 | 0.030 |
Why?
|
Bone Plates | 1 | 1999 | 468 | 0.030 |
Why?
|
Adolescent | 4 | 2021 | 88819 | 0.030 |
Why?
|
Triazoles | 1 | 2021 | 902 | 0.030 |
Why?
|
Corneal Diseases | 1 | 2001 | 535 | 0.030 |
Why?
|
MART-1 Antigen | 2 | 2007 | 62 | 0.030 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2008 | 2184 | 0.030 |
Why?
|
Cultural Diversity | 1 | 2019 | 370 | 0.030 |
Why?
|
Polyethylenes | 1 | 1998 | 289 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2018 | 11094 | 0.030 |
Why?
|
Zebrafish Proteins | 1 | 2021 | 1017 | 0.030 |
Why?
|
Iodine Radioisotopes | 1 | 1998 | 1029 | 0.030 |
Why?
|
Eye Movements | 1 | 1998 | 510 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 4565 | 0.030 |
Why?
|
Cytoskeleton | 1 | 1999 | 1179 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2019 | 1865 | 0.030 |
Why?
|
Viral Load | 1 | 2023 | 3386 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2019 | 2227 | 0.030 |
Why?
|
HIV Antibodies | 1 | 2021 | 1337 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2020 | 2510 | 0.030 |
Why?
|
Kinetics | 1 | 2021 | 6273 | 0.030 |
Why?
|
Risk Factors | 1 | 2020 | 74857 | 0.030 |
Why?
|
Cell Adhesion | 1 | 2019 | 3089 | 0.030 |
Why?
|
HLA-A Antigens | 1 | 2013 | 223 | 0.030 |
Why?
|
Aged, 80 and over | 3 | 2014 | 59515 | 0.020 |
Why?
|
Neoplasm Proteins | 3 | 2013 | 3594 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2022 | 6840 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 1999 | 21074 | 0.020 |
Why?
|
HIV Protease | 1 | 1992 | 99 | 0.020 |
Why?
|
Antibodies, Neutralizing | 1 | 2022 | 2011 | 0.020 |
Why?
|
Interleukin-10 | 1 | 2017 | 1181 | 0.020 |
Why?
|
Dendritic Cells | 1 | 2003 | 2747 | 0.020 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2020 | 1609 | 0.020 |
Why?
|
Benzamides | 1 | 2017 | 1376 | 0.020 |
Why?
|
Pyrazines | 1 | 2017 | 1204 | 0.020 |
Why?
|
Amino Acid Sequence | 2 | 2021 | 13400 | 0.020 |
Why?
|
Prostheses and Implants | 1 | 1998 | 1273 | 0.020 |
Why?
|
Hypotension | 1 | 2017 | 885 | 0.020 |
Why?
|
Transplantation, Homologous | 1 | 1999 | 4860 | 0.020 |
Why?
|
Piperazines | 1 | 2021 | 2547 | 0.020 |
Why?
|
Amino Acid Motifs | 1 | 2013 | 924 | 0.020 |
Why?
|
Syndrome | 1 | 2017 | 3270 | 0.020 |
Why?
|
Intraocular Pressure | 2 | 2001 | 1304 | 0.020 |
Why?
|
Child, Preschool | 3 | 2021 | 42511 | 0.020 |
Why?
|
Prostate | 1 | 2018 | 1758 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2003 | 4910 | 0.020 |
Why?
|
Remission Induction | 1 | 2015 | 2413 | 0.020 |
Why?
|
Vaccination | 1 | 2022 | 3431 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2014 | 13483 | 0.020 |
Why?
|
Glucocorticoids | 1 | 1998 | 2156 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 1999 | 3722 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 3665 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 4 | 2001 | 20700 | 0.020 |
Why?
|
Receptors, Natural Killer Cell | 1 | 2007 | 55 | 0.020 |
Why?
|
Prospective Studies | 2 | 2022 | 54812 | 0.020 |
Why?
|
Genomics | 1 | 2023 | 5926 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2008 | 26381 | 0.020 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily K | 1 | 2007 | 94 | 0.020 |
Why?
|
Solubility | 1 | 2009 | 1077 | 0.020 |
Why?
|
Cardiovascular Diseases | 1 | 2013 | 15647 | 0.020 |
Why?
|
Epitopes | 1 | 2013 | 2523 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2020 | 3798 | 0.020 |
Why?
|
Drug Resistance | 1 | 1992 | 1592 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2017 | 4887 | 0.020 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2019 | 2327 | 0.020 |
Why?
|
Survival Rate | 1 | 2020 | 12827 | 0.020 |
Why?
|
Cognition | 1 | 2023 | 7050 | 0.020 |
Why?
|
Pregnancy | 1 | 2008 | 30233 | 0.020 |
Why?
|
Cell Culture Techniques | 1 | 2013 | 1651 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2020 | 11200 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 1998 | 3477 | 0.020 |
Why?
|
Cohort Studies | 2 | 2019 | 41684 | 0.020 |
Why?
|
Substrate Specificity | 1 | 2009 | 1751 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2017 | 9540 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2017 | 4213 | 0.010 |
Why?
|
RNA, Messenger | 2 | 2014 | 12775 | 0.010 |
Why?
|
Indoles | 1 | 1992 | 1833 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2021 | 9601 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2019 | 14456 | 0.010 |
Why?
|
Protein Multimerization | 1 | 2009 | 959 | 0.010 |
Why?
|
Receptors, Fc | 1 | 2007 | 537 | 0.010 |
Why?
|
Disease Progression | 1 | 2020 | 13616 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2021 | 22228 | 0.010 |
Why?
|
Receptor Activator of Nuclear Factor-kappa B | 1 | 2003 | 79 | 0.010 |
Why?
|
Liver Neoplasms | 1 | 2019 | 4352 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2021 | 20137 | 0.010 |
Why?
|
Ultrasonography | 2 | 2001 | 5988 | 0.010 |
Why?
|
Centrifugation, Density Gradient | 1 | 2002 | 297 | 0.010 |
Why?
|
Laser Therapy | 1 | 1990 | 1108 | 0.010 |
Why?
|
Cell Fractionation | 1 | 2002 | 244 | 0.010 |
Why?
|
DNA, Recombinant | 1 | 2002 | 455 | 0.010 |
Why?
|
RANK Ligand | 1 | 2003 | 320 | 0.010 |
Why?
|
Torsion Abnormality | 1 | 2001 | 92 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 1992 | 5784 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8725 | 0.010 |
Why?
|
Escherichia coli | 1 | 1992 | 4210 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2017 | 22341 | 0.010 |
Why?
|
Cytomegalovirus | 1 | 2003 | 753 | 0.010 |
Why?
|
Histiocytes | 1 | 1998 | 97 | 0.010 |
Why?
|
Skin, Artificial | 1 | 1999 | 89 | 0.010 |
Why?
|
Ultraviolet Rays | 1 | 2003 | 1099 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 3 | 2001 | 36548 | 0.010 |
Why?
|
Exophthalmos | 1 | 1998 | 100 | 0.010 |
Why?
|
Osseointegration | 1 | 1998 | 269 | 0.010 |
Why?
|
Postoperative Complications | 4 | 2001 | 15808 | 0.010 |
Why?
|
Interleukin-2 | 1 | 2002 | 1894 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 3801 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2002 | 2627 | 0.010 |
Why?
|
Cell Division | 1 | 2002 | 4466 | 0.010 |
Why?
|
Mutation | 1 | 2019 | 30209 | 0.010 |
Why?
|
Up-Regulation | 1 | 2002 | 4133 | 0.010 |
Why?
|
Decompression, Surgical | 1 | 1998 | 602 | 0.010 |
Why?
|
Arabinose | 1 | 1992 | 31 | 0.010 |
Why?
|
Rabbits | 1 | 1998 | 4730 | 0.010 |
Why?
|
Verapamil | 1 | 1992 | 242 | 0.010 |
Why?
|
Restriction Mapping | 1 | 1992 | 848 | 0.010 |
Why?
|
Operon | 1 | 1992 | 371 | 0.010 |
Why?
|
Prosthesis Design | 1 | 1998 | 2111 | 0.010 |
Why?
|
Vinblastine | 1 | 1992 | 483 | 0.010 |
Why?
|
Collagen | 1 | 1999 | 2617 | 0.010 |
Why?
|
Wound Healing | 1 | 2001 | 2795 | 0.010 |
Why?
|
Vasoconstriction | 1 | 1992 | 593 | 0.010 |
Why?
|
Microscopy, Electron | 1 | 1992 | 2543 | 0.000 |
Why?
|
Calcium Channels | 1 | 1992 | 622 | 0.000 |
Why?
|
Endoscopy | 1 | 1998 | 1854 | 0.000 |
Why?
|
Fibroblasts | 1 | 1998 | 4162 | 0.000 |
Why?
|
Plasmids | 1 | 1992 | 2267 | 0.000 |
Why?
|
Blotting, Western | 1 | 1992 | 5020 | 0.000 |
Why?
|
Polymerase Chain Reaction | 1 | 1992 | 6059 | 0.000 |
Why?
|
Base Sequence | 1 | 1992 | 12405 | 0.000 |
Why?
|
Molecular Sequence Data | 1 | 1992 | 17597 | 0.000 |
Why?
|
Calcium | 1 | 1992 | 5770 | 0.000 |
Why?
|
Rats | 1 | 1992 | 23717 | 0.000 |
Why?
|